(BMS) June 24, 2017 - Combination therapy demonstrated a sustained reduction in risk of progression/death of 29% and relative improvement of 50% in progression-free survival rate of ELd (21%) compared to Ld alone (14%); the extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma; the...

(4-traders) June 23, 2017 - Early studies of weekly and twice-weekly ixazomib plus lenalidomide and dexamethasone demonstrate deep responses after induction, with deepening responses seen after single-agent ixazomib maintenance; Data to be presented during two oral sessions at the 2017 European Hematology Association (EHA) Annual Meeting.